Mabwell Launches Clinical Trial for Innovative Cancer Treatment 7MW4911

Mabwell Advances Cancer Treatment with Innovative Antibody-Drug Conjugate Trial

Mabwell, an innovation-driven biopharmaceutical company, takes a significant step forward in oncology with the initiation of a clinical trial for its novel antibody-drug conjugate (ADC), 7MW4911. On January 22, 2026, the company announces that the first patient has been dosed in a U.S. Phase I/II trial aimed at treating advanced colorectal cancer and other gastrointestinal tumors. This marks the first-in-human (FIH) trial for 7MW4911 in the United States, following its prior approval and initial dosing in China. Mabwell's commitment to tackling complex medical challenges is exemplified by this trial, which explores a promising treatment option for patients facing multidrug-resistant cancers.

The ADC, developed using Mabwell's proprietary IDDC™ platform, incorporates a specific CDH17 monoclonal antibody, designed to target the CDH17 protein often overexpressed in gastrointestinal tumors. What sets 7MW4911 apart is its innovative cleavable linker that exhibits high plasma stability, combined with a unique DNA topoisomerase I inhibitor, MF-6, which is engineered to overcome multidrug resistance—a significant hurdle in cancer treatment. Preclinical studies have shown that 7MW4911 demonstrates superior antitumor activity compared to existing MMAE/DXd-based ADCs, particularly in multidrug-resistant contexts. These findings underscore Mabwell's potential to revolutionize treatment protocols for patients who have exhausted other therapeutic options.

Mabwell's pursuit of effective therapies aligns with its mission to "Explore Life, Benefit Health." The company actively seeks to address global medical needs, particularly in oncology and aging-related diseases. Research findings from preclinical studies have garnered attention, with publications in prestigious platforms such as the 2025 American Association for Cancer Research (AACR) and Cell Reports Medicine. Nonetheless, the company remains cautious, issuing forward-looking statements that acknowledge the uncertainties surrounding safety, efficacy, regulatory approval, and commercial success of its product candidates. This transparency highlights the challenges that still lie ahead in the development of 7MW4911 and similar innovative therapies.

In addition to this pivotal trial, Mabwell's continuous focus on innovation reflects its broader strategy to advance healthcare solutions globally. The company remains committed to translating groundbreaking ideas into effective treatments, significantly impacting patients' lives. By prioritizing research and development, Mabwell not only aims to enhance its product pipeline but also to contribute to the overall advancement of cancer care.

As Mabwell progresses through this clinical trial, the biopharmaceutical community watches closely, interested in the outcomes that could reshape the treatment landscape for advanced gastrointestinal cancers. The company's innovative approach, founded on rigorous research and a commitment to addressing unmet medical needs, positions it as a key player in the evolving field of oncology.